BioUtah News
-
PhotoPharmics Announces Publication of Phase 2 Clinical Trial Results in Neurotherapeutics and Its Role in the Company’s Phase 3/Pivotal Clinical Trial
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease
-
SPARC Health Announces Second Cohort Applications, Building on Inaugural Program Success
SPARC Health, a collaborative effort between Park City Angels (PCA), BioUtah, BioHive, in partnership with Governor’s Office of…
-
SPARC Health, BioUtah Co-Host Shark Tank-Style Pitch Competition at 2026 Wilson Sonsini Entrepreneur & Investor Life Sciences Summit
Taking place on March 12, 2026, at the Hilton Salt Lake City Center, the competition provides early-stage healthcare…
-
JP Morgan Healthcare Conference Recap – Photo Gallery
Check out the photo gallery from the 2026 JP Morgan Healthcare conference in San Francisco.
-
Haemonetics to Acquire Vivasure Medical
The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular procedures.
-
BD Receives FDA 510(k) Clearance for EnCor EnCompass™ Breast Biopsy and Tissue Removal System
State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026
-
DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease
DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc…
-
Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications
Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening…
-
Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment
Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment
-
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on…
-
Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing
Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing
-
SINTX 2025 Highlights
As we look back at 2025, we’re thankful for the progress our team and partners helped drive this…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
